Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas H. Jensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Beta
- 0.56
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.60
Financials
Revenue
$0.00-100.0%Net Income
$-3.40MEBITDA
$-2.44MFree Cash Flow
$-2.56MEPS (diluted)
$-0.21Shares Outstanding (diluted)
15.91M+530257.5%Operating Expenses
$2.67MCash & Debt
$16.98MReturn of Capital
$0.00Revenue by Segment (annual)
$320.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $320.0K | $-11.23M | $-0.78 |
| 2024 | $0.00 | $-24.52M | $-15.79 |
| 2023 | $0.00 | $-11.90M | $-6031.31 |
| 2022 | $0.00 | $-16.06M | $-31799.09 |
| 2021 | $0.00 | $-26.65M | $-79074.18 |
| 2020 | $0.00 | $-6.60M | $-1698639.00 |
| 2019 | $120.0K | $-14.31M | $-189613.00 |
| 2018 | $1.46M | $-2.29M | $0.00 |
| 2017 | $1.46M | $-4.90M | $0.00 |
| 2016 | $143.3K | $-3.68M | $0.00 |
| 2015 | $362.3K | $-1.15M | $0.00 |
| 2014 | $10.0K | $-68.7K | $-0.06 |
| 2013 | $0.00 | $-81.2K | $0.00 |
Valuation
ALLRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·8d ago·Neutral
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable external partnerships
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…al Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-…
View source ↗ - Newsglobenewswire.com·53d ago·Positive
…P ® testing to accelerate and support U.S. clinical trials TARPON SPRINGS, Fla., AUGUST 14, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2026.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.21 per share
Typical surprise +20.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.21 vs $-0.25beat
- Fri, May 15$-0.17 vs $-0.22beat
- Tue, Mar 31$-0.19 vs $-0.22beat
- Fri, Nov 14$-0.19 vs $-0.23beat
- Fri, Aug 15$-0.15 vs $-0.21beat
- Fri, Apr 4$-4.73 vs $-8.10beat
Estimates and results for ALLR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALLR officers and directors.
No open-market trades in the recent filings. All 54 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALLR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.